Jan Andersson, MD, PhD, is currently Vice-President of Karolinska Institutet (Sweden), one of the world’s foremost medical universities, and a Professor in Infectious Diseases at Karolinska University Hospital (Sweden). Dr Andersson has been a member of the Nobel assembly since 2004 and a member of the Nobel Committee (which has five members) since 2007. Dr Andersson obtained his medical and doctoral degree at Karolinska Institutet and did postdoctoral research at the DNAX Research Institute, Palo Alto (California, USA) and Northwestern University Medical School (Chicago, USA). He has published 225 original publications and 60 reviews and book chapters. In 2007 and 2008 he was visiting professor at the Division of Experimental Medicine, Department of Medicine, University of California at San Francisco (UCSF). Dr Andersson is a member of the board of the Centre of Molecular Medicine (CMM) at the Karolinska University Hospital.
Louise Proulx holds a PhD in physiology from Université Laval (Canada) and pursued postdoctoral studies at Karolinska Institutet. She has nearly 30 years of experience in research and science management. She currently holds the position of Vice-President, Research and Development, and Site Head, at Vertex Pharmaceuticals Incorporated (Canada), and has also held positions at Topigen Pharmaceuticals Inc., ViroChem Pharma Inc, Hoechst Marion Roussel and BioChem Pharma Inc. Outside of the pharmaceutical industry, Dr Proulx has served as Vice-President, Business Development of Genome Quebec and Vice Principal Research at McGill University. Dr Proulx has been a member of several boards of directors including the National Research Council of Canada. She is currently a member of the board of directors of Diagnocure Inc., Genome Quebec and the Canada Foundation for Innovation.
Dr Christian Homsy, CEO of Cardio3 BioSciences said: “The appointment of Dr Andersson and Dr Proulx adds further strength and depth to our Board of Directors. Each brings a wealth of knowledge and a level of international experience and exposure that I believe can only benefit Cardio3 BioSciences and our shareholders.”